Results 201 to 210 of about 24,063,572 (372)

Detecting homologous recombination deficiency for breast cancer through integrative analysis of genomic data

Molecular Oncology, EarlyView.
This study develops a semi‐supervised classifier integrating multi‐genomic data (1404 training/5893 validation samples) to improve homologous recombination deficiency (HRD) detection in breast cancer. Our method demonstrates prognostic value and predicts chemotherapy/PARP inhibitor sensitivity in HRD+ tumours.
Rong Zhu, Katherine Eason, Suet‐Feung Chin, Paul A. W. Edwards, Raquel Manzano Garcia, Richard Moulange, Jia Wern Pan, Soo Hwang Teo, Sach Mukherjee, Maurizio Callari, Carlos Caldas, Stephen‐John Sammut, Oscar M. Rueda   +12 more
wiley   +1 more source

The influence of soil steaming on some properties of the soil and on the growth and heading of winter glasshouse lettuce. III. The influence of nitrogen form, manganese level and shading studied in sand culture experiments with trickle irrigation.

, 1970
G. Jager, J. van der Boon, G.J.G. Rauw
openalex   +2 more sources

A Kinetic Approach To The Definition Of Pathophysiology Of Low Antithrombin III (AT) Levels In Patients [PDF]

, 1981
E. B. Reeve, B. D. Leonard, R. D. Bies, Daniel R. Ambruso, William E. Hathaway   +4 more
openalex   +1 more source

Early Outcome Analysis of Management of Closed Pelvic Ring Fractures in Emergency: Conservative Versus Surgical at Level III Trauma Center in India. [PDF]

Cureus, 2022
Mishra S, Satapathy D, Zion N, Lodh U.
europepmc   +1 more source

A Cost-Benefit Analysis of Basel III: Some Evidence from the UK [PDF]

This paper provides a long-term cost-benefit analysis for the United Kingdom of the Basel III capital and liquidity requirements proposed by the Basel Committee on Banking Supervision (BCBS, 2010a).
Maximilian J. B. Hall, Meilan Yan, Paul Turner   +2 more
core  

Evaluation of KRAS and NRAS mutations in metastatic colorectal cancer: an 8‐year study of 10 754 patients in Turkey

Molecular Oncology, EarlyView.
This nationwide study evaluated KRAS and NRAS mutations in 10 754 Turkish patients with metastatic colorectal cancer. The results revealed a mutation frequency of 51.1%, with 46.6% having KRAS mutations, 4.5% having NRAS mutations, and 48.5% being wild‐type for both.
Gozde Kavgaci, Izzet Akiva, Yavuz Hakan Ozon, Hakan Berkil, Huseyin Karadayi, Omer Dizdar, Suayib Yalcin   +6 more
wiley   +1 more source

Changes in digestive enzyme levels in carp after feeding. III. Response of protease and amylase to twice-a-day feeding.

, 1976
Toshio Onishi, Shigeo Murayama, Masaaki Takeuchi   +2 more
openalex   +2 more sources

Patients in Iowa Counties Lacking Hospitals With Labor and Delivery Services Disproportionately Receive Care at Level III Maternal Care Hospitals When Undergoing Cesarean Delivery: A Retrospective Longitudinal Study. [PDF]

Cureus, 2022
Thenuwara KN, Dexter F, Ledolter J, Radke SM, Epstein RH.   +4 more
europepmc   +1 more source

Risk Measurement, Risk Management and Capital Adequacy in Financial Conglomerates [PDF]

Is there something special, with respect to risk and capital, about a financial conglomerate that combines banking, insurance and potentially other financial and non-financial activities?
Andrew Kuritzkes, Scott M. Weiner, Til Schuermann   +2 more
core  

Landscape of BRAF transcript variants in human cancer

Molecular Oncology, EarlyView.
We investigate the annotation of BRAF variants, focusing on protein‐coding BRAF‐220 (formerly BRAF‐reference) and BRAF‐204 (BRAF‐X1). The IsoWorm pipeline allows us to quantify these variants in human cancer, starting from RNA‐sequencing data. BRAF‐204 is more abundant than BRAF‐220 and impacts patient survival.
Maurizio S. Podda, Danilo Tatoni, Gianluca Mattei, Alberto Magi, Romina D'Aurizio, Laura Poliseno   +5 more
wiley   +1 more source